Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study - Eron, Joseph J.; Clotet, Bonaventura; Durant, Jacques; Katlama, Christine; Kumar, Princy; Lazzarin, Adriano; Poizot-Martin, Isabelle; Richmond, Gary; Soriano, Vincent; Ait-Khaled, Mounir; Fujiwara, Tamio; Huang, Jenny; et al. (The Journal of infectious diseases, 2013)
Keywords: Adult; Aged; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - pharmacology; Antiretroviral Therapy, Highly Active - methods; Biological and medical sciences; Drug Resistance, Viral; Female; Fundamental and applied biological sciences. Psychology; Heterocyclic Compounds, 3-Ring - administration & dosage; Heterocyclic Compounds, 3-Ring - adverse effects; Heterocyclic Compounds, 3-Ring - pharmacology; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - isolation & purification; Human immunodeficiency virus 1; Human viral diseases; Humans; Infectious diseases; Major and Brief Reports; MAJOR ARTICLES AND BRIEF REPORTS; Male; Medical sciences; Microbiology; Middle Aged; Miscellaneous; Pilot Projects; Plasma - virology; Pyrrolidinones - pharmacology; Raltegravir Potassium; RNA, Viral - blood; Treatment Outcome; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral Load; Virology; Young Adult; Immunopathology; Antiretroviral agent; HIV-1 virus; Retroviridae; AIDS; Immune deficiency; Lentivirus; Virus; Infection; Resistance; Integrase inhibitor; Treatment; Efficiency; Viral disease; Antiviral; Human immunodeficiency virus; Raltegravir